Rimegepant: A Promising Migraine Relief for Triptan-Unsuitable
- MigraineMind
- Nov 20, 2025
- 1 min read
Research Summary
A recent study published in Cephalalgia explored the effectiveness of rimegepant, a calcitonin gene-related peptide antagonist, for treating migraines in adults for whom triptans are unsuitable. The randomized, double-blind, placebo-controlled phase 4 trial involved 585 participants who were either intolerant, unresponsive, or had contraindications to triptans. Participants received a single 75-mg dose of rimegepant orally disintegrating tablet or a placebo. The study found rimegepant significantly more effective than placebo in relieving migraine pain within two hours, with 55.9% experiencing pain relief compared to 32.7% in the placebo group. The treatment was well-tolerated, with similar adverse event rates to placebo, demonstrating a promising alternative for those unable to use triptans.
Study Details
👥 Research Team: Ashina M et al.
📚 Published In: Cephalalgia
📅 Publication Date: 2025 Nov
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.